Summary Drug delivery remains a challenge in management of cancer. Approximately 12.5 million new cases of cancer are being diagnosed worldwide each year and considerable more…

It is the general consensus of scientists that cancer vaccines will become a reality. Overall the cancer treatment market continues to grow and this demand sets the stage for more…

Executive Summary This report aims to analyze the current and future potential of breast cancer pipeline by examining key fundamentals across the entire pipeline of drug more…

Overview Introduction In 2008, the six tumor types covered in this report are forecast to account for over 666,000 new cases of cancer, obviously representing an enormous mark more…

Executive Summary This report aims to analyze the current and future potential of cancer antibodies by examining key fundamentals across the entire pipeline of antibody drug more…

This report: Covers updated aspects in the oncology industry Reviews markets for each of the categories of reagents used to treat cancer and different therapies, including ch more…

Executive Summary This report aims to analyze the current and future potential of cancer vaccines by examining key fundamentals across the entire pipeline of cancer vaccine more…

Executive Summary There are today more than 200 anti-angiogenic/vascular disruptive/vascular targeting agents drugs in oncology, from early preclinical to marketed drugs. more…

Executive Summary The commercial and therapeutic success of antibodies like Rituxan, Avastin, and Erbitux will force the industry to look into the next generation of more…

Executive Summary Cancer cells frequently and possibly invariably possess apoptotic defects. In this context, apoptotic pathways provide exciting molecular targets for new more…

Executive Summary Despite the heavy investment made into brain cancer research, primary brain cancer, with glioblastoma multiforme being the most aggressive and most common more…

Executive Summary Breast cancer is the leading cause of cancer-related mortality among women worldwide. High unmet needs still persist for this tumor type. Despite recent drug more…

Executive Summary Unmet needs across the hematological malignancies remain high, with most traditional therapies conferring low levels of specificity and high toxicity. There more…

Executive Summary Cancer immunotherapy offers an attractive therapeutic addition, delivering treatment of high specificity, low toxicity and prolonged activity. In this Drug more…

Executive Summary Leukemia includes a broad variety of histological separate disorders which make the leukemia market segmented. There are today more than 240 therapeutics more…

Executive Summary Lymphoma is a broad term encompassing a variety of cancers of the lymphatic system. There are today more than 180 therapeutics targeting lymphoma, from early more…

Executive Summary Cancer of the prostate is the second most frequently diagnosed cancer in men in the US. The prostate cancer market is reaching maturity, and major players` more…

Abstract Overview Introduction Non-small cell lung cancer accounts for about 80% of all lung cancers. In 2008, the incidence of NSCLC is forecast to exceed 367,000 new more…

This new strategic report from Espicom provides a comprehensive review of current and future treatments for major blood cancer therapy areas: chronic lymphocytic leukaemia, more…

Cancer testing is one of the most important growth opportunities for the next three to five years in the diagnostics segment. The National Cancer Institute estimates that more…

This research service explores the market for therapeutics used for the treatment of breast cancer in the Unites States of America. It analyzes the various challenges faced by more…

Introduction In 2006, the NSCLC market, valued at over $3 billion in the US, Europe, and Japan, was led by the chemotherapeutic taxane, Sanofi-Aventis' Taxotere. Five existing more…

The new 6th edition of this respected management report is the essential reference work for everyone in the field. The report covers 121 companies - from the largest blue-chip more…

This research service provides a detailed description of the European prostate cancer therapeutics market with emphasis on hormonal therapies. more…

This research service explores the market for therapeutics used for the treatment of breast cancer in Europe. It analyses the various challenges faced by the pharmaceutical more…

Introduction This report, Decoding Big Pharma's R&D Strategy in Oncology, is based on five major pharmaceutical companies in the oncology arena: Bristol-Myers Squibb, more…

The launch of Sanofi Pasteur MSD's Gardasil and GSK's Cervarix has propelled cancer vaccines from research obscurity to a key area of commercial and clinical interest. But can more…

This Frost & Sullivan research service titled European Bladder Cancer Therapeutics Markets presents a concise analysis of the market that includes challenges, factors driving more…

This Frost & Sullivan research service titled European Head and Neck Cancer Therapeutics Markets provides market drivers, restraints and revenue forecasts for this market. In more…

Overview Introduction Sales of the Top 20 cancer therapy brands in each of the seven major markets totaled $24.5 billion in 2006 and are forecast to grow at a CAGR of 6.6% to more…

Overview Introduction Incidence of primary brain cancer across the seven major markets in 2007 is estimated to be 47,000. Over half of these cases will be glioblastoma multifo more…

The trend toward cost-effective skin ulcer treatment remains embedded in management programs that emphasize prevention and early intervention. New wound care products and more…

Abstract Overview Introduction Supportive care can be defined as those products used to prevent and/or treat the adverse side effects that arise as a result of the tum more…

Executive Summary The elaborate advances towards the blueprinting of the altered molecular networks that lie behind cancer development have paved the way for targeted therapy more…

Introduction Drug companies' cancer pipelines are bulging, and hundreds of new drugs are in development-the modern equivalent of a gold rush. Remarkable successes have been more…

Executive Summary "Analytical Tool - Breast Cancer Therapeutics & Competitive Insights" offers a unique tool for analyzing the vast amount of strategic possibilities that have more…

"Analytical Tool - Competitive Outlook on Apoptosis in Oncology" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in apoptosis more…

Executive Summary "Analytical Tool - Competitive Outlook on Cancer Vaccines" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in more…

"Analytical Tool - Hematological Cancers" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in R&D and business development in more…

Executive Summary Cancer vaccines offer an attractive therapeutic addition, delivering treatment of high specificity, low toxicity and prolonged activity. However, despite more…

Introduction Although novel cancer biomarkers are reported on a weekly basis, only a handful are actually translated into fully validated diagnostic tools. To fully understand more…

Introduction Unmet needs across the hematological malignancies remain high, with most traditional therapies conferring low levels of specificity and high toxicity. Pipeline more…

INTRODUCTION Cancer immunotherapeutics, in particular monoclonal antibody-based products and vaccines, are transforming the cancer treatment market and providing a whole new more…

Introduction The markets segments for therapeutics for hematological malignancies are numerous and complicated. The historical general conception that relatively low more…

The U.S. Multiple Myeloma Market is a rapidly progressing field that is set to generate over $3 billion in revenue in the coming years. The market has witnessed unprecedented more…

Introduction The ongoing evolution of cancer therapeutics and the associated increase in survival times have prompted a reevaluation of traditional methodology in the design more…

Overview Introduction Globally, esophageal cancer is the ninth most common tumor type and seventh leading cause of cancer-related death, however, its incidence fluctuates wide more…

Introduction The treatment for breast and prostate cancer are under intense progress. Cancer of the prostate is the second most frequently diagnosed cancer in men in the US more…

Introduction Overall approximately 3 million women in the US are living with breast cancer. But, even with an increasing incidence, the mortality rate has dropped slightly more…

The cancer market is highly dynamic, creating a new age of discovery and innovation driven by molecular biology, oncogenomics and new methods in cell biology. These more…

Few pharmaceutical markets will see the dramatic change that will occur in cancer therapeutics over the next four years. More than $8 billion dollars worth of new products are more…

Executive Summary With our 750 page report entitled "Top 7 Cancer Indications - Therapeutic & Competitive Insights" we present one of the largest reports published evaluating more…

Overview Introduction Unmet needs across the cancer market remain high, with most therapies conferring low levels of specificity and high toxicity. Therapeutic cancer vaccines more…

Overview Introduction Cases of endometrial cancer are set to rise in developed countries due to an increase in risk factors such as obesity. In contrast, while incidence of ce more…

Introduction The dogma for treatment of cancer has changed, with the cytotoxic drugs used in chemotherapy regimes set to lose their dominance and be used alongside targeted more…

Executive Summary In this triple analysis report BioSeeker Group has analyzed three major and intertwined areas of cancer R&D, Apoptopic agents, Antibodies and Vaccines in more…

Research Overview This Frost & Sullivan research service entitled the U.S. Colorectal Cancer Markets: Patient Outlook is an update to Frost & Sullivan's coverage of colorectal more…

Introduction Non-Hodgkin's lymphoma, consisting of 29 different malignancies of the lymphatic system, is a devastating disease: although treatable, only a small percentage of more…

Introduction The enormous economic and social burden of cancer continues to grow in the aging societies of Europe and Japan. National health care systems have the unenviable more…

Cancer continues to pose a major health burden worldwide. Prevailing therapies are extremely limited in terms of safety, tolerability, and efficacy. Meanwhile, the morbidity more…

Introduction In 2006, approximately 1.4 million U.S. residents are expected to be diagnosed with some form of cancer. Medicare's role in oncology therapy is particularly more…

This report analyzes the worldwide markets for Breast Cancer Therapeutics in US$ Million. The major product segments analyzed are Hormonal Therapy, Chemotherapy, and more…

Abstract This report analyzes the worldwide markets for Colorectal Cancer Therapeutics in US$ Million. The major product segments analyzed are Cytotoxic Therapies (5-FU more…

Introduction Lymphoma is a broad term encompassing a variety of cancers of the lymphatic system. The two main groups of lymphoma in humans are Hodgkin's disease (characterized more…

Overview Introduction Until a decade ago, 5FU/leucovorin formed the mainstay of colorectal cancer treatment but Camptosar and Eloxatin quickly established themselves as compon more…

Overview Introduction Cancer treatment continues to undergo a paradigm shift with the inclusion of molecular targeted therapies (MTT) into standard regimens. With this transit more…

Introduction With Avastin as its bright star, the therapeutic field of anti-angiogenic and vascular targeting drugs in oncology is becoming re-energized. While fragmentation more…

In this triple analysis report BioSeeker Group has analyzed three major and intertwined areas of cancer R&D, Non Small Cell Lung Cancer Therapeutics, Protein Kinase Inhibitors more…

Introduction Leukemia includes a broad variety of histological separate disorders which make the leukemia market segmented. And even though a high level of unmet medical need, more…

This research service provides market intelligence, analysis, and forecasts for the U.S. cancer in-vitro diagnostics markets. The products discussed in this research service more…

This report provides a complete insight to the technology, companies and research institutions that are driving this high-growth and promising sector. Providing... A rev more…

Introduction New approaches in vaccines, such as DNA vaccines, new combination vaccines, new formulations, novel delivery routes, new adjuvants are being explored. In the last more…

In this triple analysis report BioSeeker Group has analyzed three major and intertwined areas of cancer R&D, Melanoma Therapeutics, Antibodies and Vaccines in Oncology, which more…

Overview Introduction Breast cancer is the leading cause of cancer-related mortality among women worldwide. In 2006, more than 447,000 cases of the disease are expected to be more…

Overview Introduction The 11 tumor types covered in this report will account for over 2.3 million new cases of cancer in 2006 in the seven major pharmaceutical markets. more…